| 2008 JASN IMPACT FACTOR 7.505 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Editorials |
Academic Renal Unit, University of Bristol, Bristol, United Kingdom
Correspondence: Prof. Peter W. Mathieson, Academic Renal Unit, Southmead Hospital, Bristol BS10 5NB, United Kingdom. Phone/Fax: +44-0-117-959-5438; E-mail: p.mathieson{at}bristol.ac.uk
| Introduction |
|---|
|
|
|---|
The first podocyte-specific gene identified by studying disease-associated mutations was NPHS1, encoding nephrin4; this was swiftly followed by identification of NPHS2, encoding podocin,5 also a novel protein important in the structure and function of glomeruli.6 Since the discovery of nephrin and podocin, several other disease-associated podocyte-specific gene defects have been reported, and, undoubtedly, there will be more to come.
Mutations in different podocyte genes or different mutations in the same gene result in varying phenotypes regarding severity and age of onset of proteinuria, and it is clear that there are likely to be other disease-modifying genes or environmental influences. Moreover, congenital forms of nephrotic syndrome are rare, and a question that intrigues nephrologists and basic scientists alike is whether the more common forms of sporadic, often later onset nephrotic syndrome could also be associated with mutations or polymorphisms in podocyte-specific genes, as predisposing factors or contributors to a complex etiology involving genetic–environmental interactions. If so, then study of these genes could be clinically useful in diagnosis and prognosis, especially concerning the likelihood of corticosteroid responsiveness and the issue of likely recurrence in renal transplants for patients who progress to end-stage renal failure.
The article in this issue of JASN by Hinkes et al.,7 the product of an impressive multinational collaboration, sheds light on these issues. The study amassed 430 patients with steroid-resistant nephrotic syndrome, the vast majority of whom were the only affected family member, although the series did include 23 families with more than one affected member. The patients were screened for mutations in NPHS2 by direct sequencing of all eight exons of the gene. Eighty-two patients (19% of the total) had mutations in NPHS2. In the families with more than one affected member, the proportion with NPHS2 mutations rose to 39%. In patients with two NPHS2 mutations, the authors report that approximately 40% had one truncating (frameshift or nonsense) mutation and an additional 30% had homozygous R1308Q mutations (the "founder" NPHS2 mutation identified by Boute et al.5). These two groups of individuals nearly all developed nephrotic syndrome at an early age (<6 yr, with a mean age of onset <2 yr). The remaining 30% of patients with other mutations or variants in NPHS2 had later onset disease without any further specific link between any given genotype and age of onset (although the numbers of patients with each genotype were small). Mutation type did not affect rate of deterioration, time from onset to ESRD being the same in all groups.
Although this represents real progress, even within the groups with early presentation there was still a wide range of age of onset. Also, >80% of the collection with steroid-responsive nephrotic syndrome did not have any abnormality of NPHS2, so their proteinuria remains unexplained; clearly there is more work to be done.
The power of large multinational studies such as this one will be essential if analyses of genotype–phenotype relationships in nephrotic syndrome are to yield informative conclusions. Ideally, genetic analysis should be more widely available as a diagnostic and prognostic aid in patients presenting with nephrotic syndrome; however, at present, clinicians will need further guidance from geneticists about the interpretation of genotype–phenotype relationships. Hinkes et al. are to be congratulated for leading the way.
| DISCLOSURES |
|---|
|
|
|---|
| Footnotes |
|---|
See related article, "Specific Podocin Mutations Correlate with Age of Onset in Steroid-Resistant Nephrotic Syndrome," on pages 365–371.
| REFERENCES |
|---|
|
|
|---|
Related Article
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |